Literature DB >> 16720563

Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita.

Mohamad M Al-Rahawan, Neelam Giri, Blanche P Alter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16720563     DOI： 10.1532/IJH97.06030

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

Review 1.  Dyskeratosis congenita: molecular insights into telomerase function, ageing and cancer.

Authors:  Anna Marrone; Inderjeet Dokal
Journal:  Expert Rev Mol Med       Date:  2004-12-20       Impact factor: 5.600

2.  Telomere length measurement by fluorescence in situ hybridization and flow cytometry: tips and pitfalls.

Authors:  Gabriela M Baerlocher; Jennifer Mak; Teri Tien; Peter M Lansdorp
Journal:  Cytometry       Date:  2002-02-01

3.  Treatment of dyskeratosis congenita with granulocyte colony-stimulating factor and erythropoietin.

Authors:  B P Alter; F H Gardner; R E Hall
Journal:  Br J Haematol       Date:  1997-05       Impact factor: 6.998

Review 4.  Management of acquired aplastic anaemia.

Authors:  Judith C W Marsh
Journal:  Blood Rev       Date:  2005-05       Impact factor: 8.250

5.  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a case.

Authors:  Patrizia Comoli; Sabrina Basso; Guan-Cheng Huanga
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 6.  Dyskeratosis congenita: clinical and genetic heterogeneity. Report of a new case and review of the literature.

Authors:  R A Drachtman; B P Alter
Journal:  Am J Pediatr Hematol Oncol       Date:  1992-11

7.  Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita.

Authors:  T Güngör; S Corbacioglu; R Storb; R A Seger
Journal:  Bone Marrow Transplant       Date:  2003-03       Impact factor: 5.483

8.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113
  8 in total
  16 in total

1.  Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes.

Authors:  Ken Matsui; Neelam Giri; Blanche P Alter; Ligia A Pinto
Journal:  Br J Haematol       Date:  2013-07-25       Impact factor: 6.998

2.  Response to androgen therapy in patients with dyskeratosis congenita.

Authors:  Payal P Khincha; Ingrid M Wentzensen; Neelam Giri; Blanche P Alter; Sharon A Savage
Journal:  Br J Haematol       Date:  2014-02-12       Impact factor: 6.998

3.  How I diagnose and manage individuals at risk for inherited myeloid malignancies.

Authors: 
Journal:  Blood       Date:  2016-07-28       Impact factor: 22.113

Review 4.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

Review 5.  The role of telomere biology in bone marrow failure and other disorders.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Mech Ageing Dev       Date:  2007-11-19       Impact factor: 5.432

Review 6.  Telomere maintenance and human bone marrow failure.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

7.  Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.

Authors:  Blanche P Alter; Gabriela M Baerlocher; Sharon A Savage; Stephen J Chanock; Babette B Weksler; Judith P Willner; June A Peters; Neelam Giri; Peter M Lansdorp
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

8.  Dyskeratosis congenita.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

9.  Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.

Authors:  Shahinaz M Gadalla; Carmem Sales-Bonfim; Jeanette Carreras; Blanche P Alter; Joseph H Antin; Mouhab Ayas; Prasad Bodhi; Jeffrey Davis; Stella M Davies; Eric Deconinck; H Joachim Deeg; Reggie E Duerst; Anders Fasth; Ardeshir Ghavamzadeh; Neelam Giri; Frederick D Goldman; E Anders Kolb; Robert Krance; Joanne Kurtzberg; Wing H Leung; Alok Srivastava; Reuven Or; Carol M Richman; Philip S Rosenberg; Jose Sanchez de Toledo Codina; Shalini Shenoy; Gerard Socié; Jakub Tolar; Kirsten M Williams; Mary Eapen; Sharon A Savage
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-08       Impact factor: 5.742

Review 10.  Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.

Authors:  Suneet Agarwal
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.